Complete 12-Week Results of NORSE Eight Trial for Outlook Therapeutics®
Outlook Therapeutics announced positive 12-week results from its NORSE EIGHT trial for ONS-5010, an ophthalmic bevacizumab formulation for wet...
Scaling Cell & Gene Therapies Globally: CGT & Cellex Partnership
CGT Global, a US-based cell collection and expansion company, and Cellex Cell Professionals, a German cell therapy manufacturer, have...
ImmunityBio’s 2025 FDA Submissions After Agency Meeting
ImmunityBio announced progress in discussions with the FDA concerning its non-muscle invasive bladder cancer (NMIBC) and non-small cell lung...
Solid Biosciences: Advancing Neuromuscular and Cardiac Gene Therapy
Solid Biosciences provided a corporate update highlighting its expanded clinical pipeline and 2025 objectives, focusing on genetic medicines for...
SIL-204 Shows Synergy with Chemotherapies in Preclinical Pancreatic Cancer Study
Silexion Therapeutics (NASDAQ: SLXN) announced promising preclinical results for SIL-204, its second-generation siRNA therapy targeting KRAS-mutated cancers. The data...
Radical Catheter’s Neurovascular Device Gets FDA Clearance
Radical Catheter Technologies, backed by NeuroTechnology Investors, received FDA 510(k) clearance for its 8F catheter, expanding its neurovascular product...
ATTRalus’ Pan-Amyloid Diagnostic Enters Phase 3 Trial
Brigham and Women’s Hospital has initiated enrollment for the Phase 3 REVEAL study of 124I-evuzamitide (AT-01), a diagnostic imaging...
Glaukos iDose Shows Positive Clinical Results
Glaukos Corporation announced positive clinical updates for its iDose® sustained-release drug delivery platform for glaucoma and ocular hypertension. The...
Omada Health Weight Maintenance After GLP-1: New Analysis Shows Successful Results
Omada Health’s analysis reveals that participants in their GLP-1 Enhanced Care Track maintained weight loss 16 weeks after discontinuing...
Umoja Biopharma Gets $100M Series C for In Vivo CAR T-cell Pipeline
Umoja Biopharma, a clinical-stage company developing •in vivo• cell therapies, secured $100 million in Series C funding. The round...